ID 120040002
Alternative Names: ID-120040002Latest Information Update: 28 Dec 2022
At a glance
- Originator Ildong Pharmaceutical
- Class Antiulcers; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastrointestinal disorders
Most Recent Events
- 07 Dec 2022 Phase-I clinical trials in Gastrointestinal disorders (In volunteers) in South Korea (unspecified route) (NCT05663879)
- 03 Jan 2022 Preclinical trials in Gastrointestinal disorders in South Korea (unspecified route) (Ildong pharmaceutical pipeline,
- 03 Jan 2022 Ildong Pharmaceutical announces intention to submit IND application for Gastrointestinal disorders (Ildong pharmaceutical pipeline,